Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) – Research analysts at Jefferies Group increased their Q2 2018 earnings per share (EPS) estimates for Aevi Genomic Medicine in a report issued on Wednesday, May 16th. Jefferies Group analyst M. Andrews now anticipates that the biotechnology company will post earnings of ($0.15) per share for the quarter, up from their prior forecast of ($0.17). Jefferies Group also issued estimates for Aevi Genomic Medicine’s Q3 2018 earnings at ($0.16) EPS, Q4 2018 earnings at ($0.15) EPS, FY2018 earnings at ($0.61) EPS, FY2019 earnings at ($1.27) EPS, FY2020 earnings at ($1.60) EPS, FY2021 earnings at ($1.36) EPS and FY2022 earnings at ($1.40) EPS.
Aevi Genomic Medicine (NASDAQ:GNMX) last announced its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01).
Separately, ValuEngine raised shares of Aevi Genomic Medicine from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd.
Shares of Aevi Genomic Medicine opened at $1.62 on Friday, MarketBeat reports. Aevi Genomic Medicine has a 52-week low of $1.50 and a 52-week high of $1.53.
A number of hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its stake in Aevi Genomic Medicine by 515.8% in the fourth quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 78,400 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Aevi Genomic Medicine by 4,715.1% in the first quarter. JPMorgan Chase & Co. now owns 101,118 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 99,018 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Aevi Genomic Medicine by 433.7% in the third quarter. Wells Fargo & Company MN now owns 130,662 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 106,178 shares during the last quarter. 20.41% of the stock is currently owned by hedge funds and other institutional investors.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.